By: Dr. Jorge Enrique Solano-López F.A.C.P
Papel de las estatinas en el tratamiento intervencionista de los síndromes coronarios agudos
José Abelardo López 2013-02-21
Anti-Lipid Therapy in PCI Patients: Monotherapy with Statins or Combination?
According to several studies, in patients with high-risk atherosclerotic disease, such as those affected by coronary artery disease, achieving target LDL levels through high-intensity statin therapy has been shown to lead to a significant reduction in long-term cardiovascular events. Therefore, the management of dyslipidemia has become a fundamental pillar of secondary prevention. However, reaching such...
Could Statins Do More than Lower Cholesterol in COVID-19 Patients?
A history of acute myocardial Infarction, cardiac failure or hyperlipidemia has been associated with increased mortality of COVID-19. Observational studies have suggested statins might reduce death risk from COVID-19, in addition to lowering cholesterol. Statins have anti-inflammatory and antithrombotic effects that could play a role in the course of the infection. Other studies have arrived...
Reducing Chronic Inflammation in Atherosclerosis with an Old Drug
Inflammation plays a crucial role in atherosclerosis progression. Recently, the COLCOT study has shown the benefits of colchicine in cardiovascular events. This good old drug has an inflammatory effect which attenuates the NLRP3 cascade. This explains its effect on uric acid crystals in gout, which might be the same on atherosclerosis cholesterol crystals. This study...
AHA 2020 | Statins: Confirmed Benefits for the Elderly
Elderly patients (>70) with high cholesterol levels have been systematically excluded from randomized studies on statins, despite their higher risk of cardiovascular events. Presented at AHA 2020 Scientific Sessions and published simultaneously in the Lancet, along comes this primary prevention study including patients between 70 and 100 years of age. The use of therapies to...
Post-MI Colchicine: Cost-Effective with Good Results
Low colchicine doses reduce the risk of post-AMI ischemic events according to the COLCOT trial, originally presented at AHA 2019 scientific sessions, and simultaneously published in NEJM. The new information delivered at the virtual ACC 2020 addresses its cost-effectiveness. Colchicine is an anti-inflammatory drug indicated in the treatment of gout and pericarditis, but its price...
Virtual ACC 2020 | Statins Could Also Protect Against Chemotherapy Cardiotoxicity
This retrospective study has shown a reduction in hospitalization for cardiac failure in patients who were already using statins receiving anthracycline and trastuzumab in the context of breast cancer. The study was to be presented during the ACC 2020 scientific sessions together with the World Congress of Cardiology. However, it had to be called off...
The Elderly and Polypharmacy: What to Discontinue
We often receive elderly poly-medicated patients (with more than 10 different drugs) who ask us to reassess these prescriptions and, if possible, discontinue some drugs. The reasons are many: they forget to take it, mix up intakes or drugs, and of course, most often find it expensive. Statins are one of the most expensive drugs...
Secondary Prevention: A Responsibility We Should Not Delegate
After coronary angioplasty, the use of drugs whose efficacy for the reduction of major events has been proven declines over time, which is associated with worse patient prognosis. Sometimes, without meaning to, we convey to patients the idea that, once the stent has been implanted, the artery is “cured” or that the only potential future...
- 1
- 2